SYHA1813
Phase 2Small molecule
SYHA1813 is one of 40 small molecule programs targeting Meningioma. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
45 competitors in Locally Advanced or Metastatic Solid Tumors
#DrugCompanyPhaseTrials
1Tecentriq
RochePhase 2
Keytruda
Merck & Co.Phase 2
Afinitor
NovartisPhase 2
Vitrakvi
BayerPhase 2
Stivarga
BayerPhase 2
OPDUALAG
Bristol-Myers SquibbPhase 2
Cabometyx
Bristol-Myers SquibbPhase 1
Budigalimab
AbbViePhase 1
Livmoniplimab
AbbViePhase 1
Nab-Sirolimus
MMirati Therapeutics Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Meningioma1 trial
A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma
Not yet recruiting·SShanghai Runshi Pharmaceutical Technology Co., Ltd·Phase 2·NCT06739213·56 enrolled
Oral1 trial
Locally Advanced or Metastatic Solid Tumors1 trial
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Not yet recruiting·SShanghai Runshi Pharmaceutical Technology Co., Ltd·Phase 1/2·NCT06682611·380 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SYHA1813. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details